Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276781 · ClinicalTrials.gov registry record
BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients
A clinical trial of Peripheral Arterial Disease, sponsored by Northwestern University.
- Completed
- Registry status
- 595
- Enrollment target
- 6
- Study locations
NCT02276781 is a study of Peripheral Arterial Disease that has completed, run by Northwestern University. The registered enrollment target is 595 participants, below the 4,199-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT02276781, a study of Peripheral Arterial Disease, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 595 participants
- Enrollment target
- 6
- Study locations
Study Summary
The investigators hypothesize that among people with lower extremity peripheral artery disease (PAD), biomarker levels are higher during time periods immediately preceding an acute coronary event compared to time periods not immediately preceding an acute coronary event. Biomarkers the investigators will study are CRP, SAA, and D-dimer. Biomarkers will be measured at baseline and every two months during follow-up. The primary aims of this study are as follows. Specific Aim #1. Among participants with PAD who experience an acute coronary event during follow-up, the investigators will determine whether biomarker levels measured immediately prior to the coronary event are higher than levels that do not immediately precede coronary events. Specific Aim #2, Part 1. The investigators will determine whether participants who experience a coronary event (cases) have higher biomarker levels at the visit immediately prior to the event than participants who have not experienced a coronary event (controls) at the time of the case event. Specific Aim #2, Part 2. The investigators will determine whether participants who experience a coronary event (cases) have a greater increase in biomarkers during the time period leading up to the event compared to participants who have not experienced a coronary event (controls). To achieve these aims, the investigators will enroll up to 650 participants with PAD and follow them prospectively, measuring blood samples every two months, and ascertaining the presence of acute coronary events every two months.
Conditions Studied
Study Locations (6)
Illinois
- Mt. Sinai Medical Center - Chicago
- Northwestern University Feinberg School of Medicine - Chicago
- Jesse Brown Veterans Administration Medical Center - Chicago
- Rush Medical Center - Chicago
- University of Chicago Medical Center - Chicago
- St. Joseph's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02276781
The ClinicalTrials.gov registry entry for NCT02276781 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,199-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (86% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02276781 reports 6 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02276781 about?
NCT02276781 is a clinical study titled "BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients". The investigators hypothesize that among people with lower extremity peripheral artery disease (PAD), biomarker levels are higher during time periods immediately preceding an acute coronary event compared to time periods not immediately preceding an acute coronary event. Biomarkers the investigators...
What is the current status of trial NCT02276781?
This trial is currently completed. The enrollment target is 595 participants. The study started on 2009-09. Estimated completion is 2013-01.
What conditions does trial NCT02276781 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
Who is sponsoring clinical trial NCT02276781?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02276781 being conducted?
This trial has 6 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.